Overview

Tinostamustine and Nivolumab in Advanced Melanoma

Status:
Recruiting

Trial end date:
2024-03-15

Target enrollment:

Participant gender:

Summary

This trial is a first-in-human drug combination with the first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule Tinostamustine (EDO-S101) and the anti-PD-1 monoclonal antibody Nivolumab in patients with refractory, locally advanced or metastatic melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

Markus Joerger

Treatments:

Nivolumab